You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

human cyclin G1 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals

Not yet recruiting
  • Preterm Labor
    • (no location specified)
    May 9, 2023

    Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

    Recruiting
    • Neurofibromatosis 1
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Skin Health and Quality of Life in Patients Receiving

    Not yet recruiting
    • Lung Cancer
    • +7 more
    • EQ-5D-5L questionnaire
    • +2 more
    • Roma, Italy
      Roberto Iacovelli
    May 17, 2023

    Pancreatic Cancer, Osteosarcoma, MPNST (Malignant Peripheral Nerve Sheath Tumor) Trial in Santa Monica (DeltaRex-G)

    Available
    • Pancreatic Cancer
    • +6 more
    • Santa Monica, California
      Sarcoma Oncology Research Center, LLC
    Jan 20, 2022

    Extensive-stage Small-cell Lung Cancer Trial (Trilaciclib, Placebo, Topotecan)

    Not yet recruiting
    • Extensive-stage Small-cell Lung Cancer
    • (no location specified)
    May 22, 2023

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Radiotherapy
    • +4 more
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Sep 14, 2023

    Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

    Active, not recruiting
    • Metastatic Breast Cancer
    • Hospitalet de Llobregat, Barcelona, Spain
    • +6 more
    Jan 23, 2023

    Personalised Disease Monitoring in Metastatic Breast Cancer

    Recruiting
    • Breast Cancer Metastatic
    • Estrogen Receptor-positive Breast Cancer
      • Gothenburg, Sweden
      • +6 more
      Dec 7, 2022

      Influenza Prevention Trial in Lenexa, Metairie, Cincinnati (INFLUENZA G1 mHA, Placebo, Al(OH)3)

      Recruiting
      • Influenza Prevention
      • INFLUENZA G1 mHA
      • +2 more
      • Lenexa, Kansas
      • +2 more
      Jun 5, 2023

      Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor Trial in United States (CDK Inhibitor

      Active, not recruiting
      • Advanced Malignant Solid Neoplasm
      • +2 more
      • CDK Inhibitor AT7519
      • +3 more
      • Washington, District of Columbia
      • +5 more
      Oct 18, 2022

      Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer Trial in Oklahoma City, Houston (AO-252)

      Recruiting
      • Triple Negative Breast Cancer
      • +2 more
      • Oklahoma City, Oklahoma
      • +1 more
      Nov 13, 2023

      Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

      Not yet recruiting
      • Advanced Solid Tumor
      • Non-small Cell Lung Cancers
      • Houston, Texas
        M D Anderson Cancer Center
      Nov 15, 2023

      Norovirus Infections, Norwalk Gastroenteritis Trial (Human Norovirus Bivalent (G?.1/G?.4)Vaccine,Recombinant (Hansenula

      Not yet recruiting
      • Norovirus Infections
      • Norwalk Gastroenteritis
      • Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
      • placebo
      • (no location specified)
      Jun 14, 2023

      COPD (COPD), Alpha1-Antitrypsin Deficiency Trial (ARALAST NP, Another Available A1PI)

      Not yet recruiting
      • Chronic Obstructive Pulmonary Disease (COPD)
      • Alpha1-Antitrypsin Deficiency
      • ARALAST NP
      • Another Available A1PI
      • (no location specified)
      Jul 18, 2022

      Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

      Completed
      • Advanced Solid Tumor
      • Inosine 0.2g orally 3 times/day
      • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
      • Beijing, Beijing, China
        Qin li
      Mar 30, 2023

      Alpha1-Antitrypsin Deficiency Trial in United States (Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human))

      Recruiting
      • Alpha1-Antitrypsin Deficiency
      • Alpha-1 15%
      • Liquid Alpha1-Proteinase Inhibitor (Human)
      • Gainesville, Florida
      • +5 more
      Jan 13, 2023

      Time in Range Trial in Cairo (Dipeptidyl peptidase-4 inhibitors)

      Completed
      • Time in Range
      • Dipeptidyl peptidase-4 inhibitors
      • Cairo, Egypt
        Nancy Elbarbary
      Aug 26, 2023

      Solid Tumors Trial (ARTS-021, CDK 4/6 inhibitor, Fulvestrant 50 MG/ML Prefilled Syringe)

      Not yet recruiting
      • Solid Tumors
      • (no location specified)
      May 17, 2023

      Pain Trial in Vienna (TRPA1-inhibitor, TRPV1-inhibitor, TRPM3-inhibitor)

      Recruiting
      • Pain
      • Vienna, Austria
        Medical University of Vienna
      Jun 13, 2022

      Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC Trial in Adelaide (BBP-398, sotorasib)

      Recruiting
      • Solid Tumor, Adult
      • +3 more
      • Adelaide, South Australia, Australia
        Cancer Research SA
      Aug 15, 2022

      Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston

      Recruiting
      • Recurrent Lung Non-Small Cell Carcinoma
      • +3 more
      • Durvalumab
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Oct 10, 2022

      Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma Trial in Portland (procedure, drug,

      Recruiting
      • Anatomic Stage IV Breast Cancer AJCC v8
      • Metastatic Triple-Negative Breast Carcinoma
      • Biopsy
      • +6 more
      • Portland, Oregon
        OHSU Knight Cancer Institute
      Jul 29, 2022

      Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

      Recruiting
      • Breast Cancer
      • Saint Louis, Missouri
      • +2 more
      Jan 12, 2023

      Breast Cancer, Breast Tumor, Breast Cancer Stage IV Trial in San Juan (MBQ-167)

      Recruiting
      • Breast Cancer
      • +2 more
      • San Juan, Puerto Rico
        FDI Clinical Research
      Oct 4, 2023

      Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

      Recruiting
      • Malignant Pleural Mesothelioma, Advanced
      • Oncolytic Adenovirus H101
      • Programmed death receptor-1 inhibitor
      • Tianjin, Tianjin, China
        Tianjin Medical Unversity Second Hospital
      Sep 2, 2023